Sugi Holdings (7649) Q3 2026 earnings summary

Executive summary

• Net sales for the nine months ended November 30, 2025, rose 18.2% year-over-year to ¥750,127 million, driven by strong Dispensing Pharmacy Business performance.

• All major profit metrics (EBITDA, operating, ordinary, and net profit) showed significant year-over-year increases, with operating profit up 18.7% to ¥34,137 million.

• Profit attributable to owners of parent surged 87.1% year-over-year to ¥35,667 million.

• Comprehensive income nearly doubled, up 96.0% year-over-year to ¥36,146 million.

Financial highlights

• FY2025 3Q cumulative net sales: ¥750,127 million, up 18.2% year-over-year; gross profit: ¥234,692 million, up 20.1%.

• EBITDA rose 20.3% to ¥200,555 million; operating profit up 18.7% to ¥34,137 million.

• Ordinary profit increased 18.2% to ¥49,079 million; profit attributable to owners of parent up 87.1% to ¥35,667 million.

• 3Q (Sep–Nov) net sales: ¥249,955 million, up 13.2% year-over-year; gross profit: ¥78,944 million, up 13.2%.

• Basic earnings per share for the period were ¥197.09, compared to ¥105.36 in the prior year.

Outlook and guidance

• FY2025 earnings forecast was revised in 1Q; actuals for 3Q cumulative net sales and gross profit exceeded budget.

• Full-year net sales forecasted at ¥1,005,000 million, up 14.5% year-over-year.

• Full-year EBITDA projected at ¥70,000 million, up 15.8% year-over-year.

• Profit attributable to owners of parent expected to reach ¥44,200 million, a 72.1% increase year-over-year.

• Full-year existing store sales growth projected at +4.5%.